Monoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy

dc.contributor.authorJuliá Palacios, Natalia
dc.contributor.authorMolina Anguita, Cristina
dc.contributor.authorSigatulina Bondarenko Maria
dc.contributor.authorCortès Saladelafont, Elisenda
dc.contributor.authorAparicio, Javier
dc.contributor.authorCuadras, Daniel
dc.contributor.authorHorvath, Gabriella
dc.contributor.authorFons, Carmen
dc.contributor.authorArtuch Iriberri, Rafael
dc.contributor.authorGarcía Cazorla, Àngels
dc.date.accessioned2026-07-02T12:04:52Z
dc.date.available2026-07-02T12:04:52Z
dc.date.issued2022-01-31
dc.date.updated2026-07-02T12:04:52Z
dc.description.abstractAim: To study neurotransmitter status in children with early epileptic and developmental and epileptic encephalopathy (DEE) and to explore the clinical response to dopaminergic and serotoninergic therapies in a group of patients. Method: Two hundred and five patients (111 males [54.1.%] and 94 females [45.9%], mean age 10 months at the onset of epilepsy [SD 1year 1month], range 0–3year) with epileptic encephalopathy/DEE were recruited, including those with West syndrome, Ohtahara syndrome, early myoclonic encephalopathy, epilepsy of infancy with migrating focal seizures, myoclonic encephalopathy in non-progressive disorders, infantile spasms, Doose syndrome, Lennox–Gastaut syndrome, Landau–Kleffner syndrome, and those unclassified. Cerebrospinal fluid (CSF) neurotransmitter studies and patients' medical records were reviewed. Additionally, we present clinical data of 10 patients with low CSF neurotransmitter levels who received dopaminergic/serotoninergic treatments. Results: Abnormal neurotransmitter values were identified in 68 (33%) patients. 5-Hydroxyindoleacetic acid (5-HIAA) deficit was the most prevalent alteration (91%). Low CSF 5-HIAA levels were significantly higher in 1- to 3-year-old children. A negative significant correlation was found between 5-HIAA levels and epilepsy duration before CSF study (Spearman's ρ=−0.191, p=0.007). Abnormalities in deep grey matter were associated with low levels of CSF homovanillic acid and 5-HIAA. Ten patients with low CSF neurotransmitter levels received dopamine and/or serotonin therapies. Six of them showed initial decrease of seizure frequency and severity and maintained improvement in some neurodevelopmental skills. Interpretation: A considerable number of patients showed neurotransmitter abnormalities. Age at seizure onset and duration of epilepsy before CSF study were the principal factors related to neurotransmitter depletion. Early monoamine supplementation would seem advisable as a neuroprotective strategy.
dc.format.extent9 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec770377
dc.identifier.issn0012-1622
dc.identifier.pmid35833444
dc.identifier.urihttps://hdl.handle.net/2445/230389
dc.language.isoeng
dc.publisherWiley
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1111/dmcn.15140
dc.relation.ispartofDevelopmental Medicine & Child Neurology, 2022, vol. 64, num.7, p. 915-923
dc.relation.urihttps://doi.org/10.1111/dmcn.15140
dc.rightscc-by-nc-nd (c) Juliá Palacios, Natalia et al., 2022
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject.classificationLíquid cefalorraquidi
dc.subject.classificationEncefalopatia mioclònica infantil
dc.subject.classificationHistòries clíniques
dc.subject.otherCerebrospinal fluid
dc.subject.otherInfantile spasms
dc.subject.otherMedical records
dc.titleMonoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
938549.pdf
Mida:
594.64 KB
Format:
Adobe Portable Document Format